Immune Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-464-2677
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions
What is Immune Pharmaceuticals' stock symbol?
Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."
How were Immune Pharmaceuticals' earnings last quarter?
Immune Pharmaceuticals Inc (NASDAQ:IMNP) issued its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.05. View Immune Pharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Immune Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immune Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Immune Pharmaceuticals.
Has Immune Pharmaceuticals been receiving favorable news coverage?
Media stories about IMNP stock have been trending neutral on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Immune Pharmaceuticals earned a news sentiment score of 0.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Immune Pharmaceuticals.
Who are some of Immune Pharmaceuticals' key competitors?
Some companies that are related to Immune Pharmaceuticals include Targeted Medical Pharma (TRGM), Spotlight Innovation (STLT), Mabvax Therapeutics (MBVX), Orexigen Therapeutics (OREXQ), Inspyr Therapeutics (NSPX), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Concordia International (CXRX), Egalet (EGLT), Eleven Biotherapeutics (EBIO) and Epirus Biopharmaceuticals (EPRSQ).
What other stocks do shareholders of Immune Pharmaceuticals own?
Who are Immune Pharmaceuticals' key executives?
Immune Pharmaceuticals' management team includes the folowing people:
- Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
- Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)
- Mr. Christine J. Petraglia, Director of Investor Relations
- Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
- Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc
How big of a company is Immune Pharmaceuticals?
What is Immune Pharmaceuticals' official website?
How can I contact Immune Pharmaceuticals?
Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected]
MarketBeat Community Rating for Immune Pharmaceuticals (NASDAQ IMNP)
MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
